文献速递外周动脉疾病

血液透析合并外周动脉疾病患者按原发肾病分层的腔内治疗临床结局

Clinical Outcomes after Endovascular Therapy Among Hemodialysis Patients with Peripheral Artery Disease Stratified by the Primary Kidney Disease.
PubMed 文献 · Ann Vasc Surg · 2021-01-05

这项回顾性观察研究纳入142例接受腔内治疗的症状性外周动脉疾病血液透析患者,按原发肾病分为高血压肾硬化组、糖尿病肾病组和慢性肾小球硬化组。中位随访372天,高血压肾硬化与主要不良事件风险增加相关,CLI、高血压肾硬化和BNP水平是MAE的独立预测因素。

要点

  • 高血压肾硬化组患者年龄更大、透析龄更短,靶病变更长。
  • 高血压肾硬化与EVT后主要不良事件风险增加独立相关。
  • CLI和BNP水平也是MAE的独立预测因素。

核心结论

  • 在血液透析合并PAD患者中,高血压肾硬化与EVT后MAE风险增加相关。

研究设计与样本

  • 回顾性观察研究,纳入142例接受EVT的症状性PAD血液透析患者,男性103例,年龄74±8岁。
  • 按透析原因分为高血压肾硬化组26例、糖尿病肾病组85例和慢性肾小球硬化组31例。

主要发现

  • 高血压肾硬化组年龄81±6岁,大于糖尿病肾病组72±8岁和慢性肾小球硬化组74±8岁,P<0.001。
  • 高血压肾硬化组透析龄2.4年,短于糖尿病肾病组6.8年和慢性肾小球硬化组11.2年,P<0.001。
  • CLI在高血压肾硬化组15例(58%)、糖尿病肾病组52例(61%)、慢性肾小球硬化组10例(32%)。
  • 高血压肾硬化组靶病变长度155±101 mm,长于糖尿病肾病组108±77 mm和慢性肾小球硬化组98±76 mm,P=0.020。
  • 中位随访372天(IQR 198-730天),Kaplan-Meier分析显示高血压肾硬化与MAE风险增加相关(χ2 11.6;P=0.003)。

关键数值与推荐

  • 多因素Cox回归显示CLI(HR 3.91,P<0.001)、高血压肾硬化(HR 2.88,P<0.001)和BNP水平(HR 1.00,P=0.001)是MAE的独立预测因素。
  • 主要结局MAE包括靶病变血运重建、大截肢和全因死亡。

临床怎么用

  • 对血液透析合并PAD患者行EVT前,应关注原发肾病类型,高血压肾硬化患者可能需更密切随访。
  • CLI和BNP水平升高提示EVT后MAE风险较高,可用于风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of this study was to investigate the clinical characteristics of hemodialysis patients with peripheral artery disease (PAD) and the outcomes after endovascular therapy (EVT) in such patients stratified by the primary kidney disease. METHODS: This retrospective observational study evaluated 142 consecutive hemodialysis patients with symptomatic PAD who underwent EVT (men: n = 103, age: 74 ± 8 years). Patients were divided into 3 groups in accordance with the reason for hemodialysis: hypertensive nephrosclerosis (HTN [n = 26]), diabetic nephropathy (DN [n = 85]), and chronic glomerulosclerosis (CGN [n = 31]). The primary outcome was major adverse event(s) (MAEs), including target lesion revascularization, major amputation, and all-cause death. Clinical characteristics and outcomes were compared among the 3 groups. RESULTS: Patients with HTN were older (81 ± 6 years vs. 72 ± 8 years vs. 74 ± 8 years; P < 0.001) and had a shorter hemodialysis vintage (2.4 years vs. 6.8 years vs. 11.2 years; P < 0.001) than those with DN and CGN. Critical limb ischemia (CLI) affected 15 (58%) patients in the HTN group, 52 (61%) in the DN group, and 10 (32%) in the CGN group. Target lesion length was longer in patients with HTN than in those in the other groups (155 ± 101 mm vs. 108 ± 77 mm [DN] vs. 98 ± 76 mm [CGN]; P = 0.020). During a median follow-up period of 372 days (interquartile range, 198-730 days), Kaplan-Meier curve analysis revealed that HTN was associated with an increased risk for MAEs (χ2 11.6; P = 0.003). Furthermore, multivariate Cox regression analysis revealed that CLI, HTN, and B-type natriuretic peptide levels were independent predictors of MAE (hazard ratio 3.91, 2.88, and 1.00; P < 0.001, P < 0.001, and P = 0.001, respectively). CONCLUSIONS: Among hemodialysis patients with PAD, HTN was associated with an increased risk for MAEs after EVT.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Iiya M, Hikita H, Yoshikawa H, et al. Clinical Outcomes after Endovascular Therapy Among Hemodialysis Patients with Peripheral Artery Disease Stratified by the Primary Kidney Disease. Ann Vasc Surg. 2021. PMID: 33418070. doi:10.1016/j.avsg.2020.11.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。